differentiated forms, and finally to ATC through chromosomal instability and a series of sequential molecular alteration. 2, 7 The emergence of a more complex genotype and specific mutations in genes such as BRAF are indicative of a more aggressive phenotype. 2 Prerequisite molecular features of ATC are p53 mutations in 80%, RAS mutations in 70%, BRAF mutations in 30-60%, and mutations of β-catenin in 70% of all ATC. 2, 8 Overexpression of the epidermal growth factor receptor and cyclin E and D is evident in 60-80% and 70%, respectively. 6, 9 Expression of the peroxisome proliferator-activated receptor gamma (PPAR-γ) and overexpression of aurora A and B are frequently found in ATC. 6, [10] [11] [12] Further potential targets in ATC are the p53-MDM2 interaction, 6, 13 Bcl-2, and angiogenesis. 6 Additional information is provided in Table 1 .
Potential Targets in Medullary Thyroid Cancer
The development of hereditary MTC is strongly associated with the activation of the RET proto-oncogene. 4 RET mutations are found in up to 98% of hereditary MTC and in up to 35-50% of sporadic MTC. 4 Mutated RET provides mitogenic and survival signals. Loss of heterozygosity in the von-Hippel-Lindau disease tumor suppressor locus occurs at the somatic level in familial MTC. 14 This leads to increased expression of the hypoxia-inducible factor I (HIF-I), which promotes tumor angiogenesis by overexpression of vascular endothelial growth factor (VEGF). 4, 15 In addition to angiogenesis as a promising target, mutations of pRb, PTEN, and cyclin-dependent kinase inhibitors are of potential clinical relevance. 4 As suggested by pre-clinical studies, targeting the RAS-RAF-ERK, PI3K-AKT, and nuclear factor kappa B (NF-κB) pathways holds promise. 4, 16 Inhibition of growth factor receptors such as IGF-I receptor and fibroblast growth factor reduced growth of tumour cells in vitro. 4, 17 For additional information, see Table 1 .
Medullary Thyroid Cancer

Prognosis and Standard Treatment
In MTC, the main independent prognostic indicators of recurrence of disease and mortality are the patient's age and the extent of disease at the time of diagnosis. 3 The pre-operative level of calcitonin predicts the probability of achieving biochemical remission and normalization of calcitonin after initial treatment correlating with a definite cure in about 95% of patients. 3 However, detectable levels of calcitonin after initial treatment do not rule out long-term survival. 3 In asymptomatic patients harboring RET germline mutations, thyroidectomy is performed preferably before the occurrence of MTC.
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Surgical treatment with total thyroidectomy and lymph-node dissection of ipsilateral and central compartments is the cornerstone of primary treatment of hereditary or sporadic MTC. 3, 4 In patients without lymph-node involvement, calcitonin levels are below the detection level in 60-90% at two to three months following primary resection. 4 Persistent disease has to be considered if calcitonin remains detectable. There seems to be a positive correlation between calcitonin level and tumor burden. 4 In cases of the disease remaining or of relapse with tumor mass in the neck or mediastinum, re-operation is usually indicated, but the probability of biochemical cure is less than 40%. 4 In patients with persistently elevated calcitonin levels, external radiation therapy may decrease the risk for recurrence. 19 Distant metastases that often affect multiple organs, particularly the lung, bone, and liver, are the main cause of disease-related death. 4 Once distant metastases are present, survival rates decline to 25%
at five years and to 10% at 10 years. 4 Relief of symptoms is the major aim of treatment of metastatic disease. Loperamide or somatostatin analogs could be effective to transiently control calcitonin-induced diarrhea. 4, 20 In addition, somatostatin analogs alone or in combination with interferon have some efficacy in reducing serum calcitonin levels but rarely induce tumor remissions. 20 Bone metastases are treated by surgery, external radiation, or chemoembolization and application of bisphosphonates. 4 Chemoembolization of clinically dominant liver metastasis may be active in reducing tumor burden and controlling tumor-associated symptoms, particularly diarrhea.
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The effect of chemotherapy on overall survival cannot be properly assessed because of an insufficient number of patients in a few prospective clinical trials. However, chemotherapy has the potential to improve symptoms and thus should be considered in the palliative treatment situation at disease progression. Table 2 ). Initial results from phase II trials with vandetanib, axitinib, or motesanib show some partial responses and a large proportion of prolonged disease stabilization. 4, 5 The data available at present indicate that not all MTC could sufficiently be treated by targeting only RET. The optimal duration of therapy is yet to be defined, and the impact of such a treatment on overall survival and prognosis is still unclear. Heat shock protein 90 is a chaperone that acts to stabilize growth factor receptors and cell signaling molecules. Its inhibition leads to RAF-1 depletion and inhibition of MAPK activation. A current phase II study is recruiting patients with locally unresectable differentiated thoracic cancer or MTC to be treated with 17-allylaminogeldanamycin (17AAG), a heat shock protein 90 inhibitor (see Figure 1 ).
Anaplastic Thyroid Cancer
Prognosis and Current Treatment
Although ATC accounts for only 1.6% of all thyroid cancers, it is responsible for more than half of the 1,200 deaths attributed to thyroid cancer in the US each year. 23 Fortunately, the incidence of ATC has been declining over the past few years despite an increase in the incidence of well-differentiated thyroid tumors. The mean age at diagnosis is 55-65 years, and the incidence peaks in the sixth to seventh decade. However, the optimal sequence of surgery, radiation, and chemotherapy is still a matter of debate. 1 It is generally agreed that a complete resection of the local tumor either before or subsequent to radiochemotherapy may improve the overall prognosis.
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In earlier series, surgery is commonly used as first-line treatment in resectable cases, followed by either radiation or radio- A randomized, prospective, multicenter clinical trial is necessary to finally clarify the question of the optimal sequence of multimodality treatment.
Molecular Targeted Therapy
New insights into molecular treatment options for ATC were mainly derived from pre-clinical in vitro or in vivo studies. PPAR-γ is a member of a superfamily of nuclear hormone receptors. High expression of PPAR-γ has recently been described in ATC cell lines. and Table 2 and Figure 1 ). Combretastatin A, an anti-endothelial agent that exerted some activity in ATC as a single agent, 5 is currently being studied in ATC in combination with paclitaxel and carboplatin. Several further molecular targeted therapies are currently being studied in pre-clinical models. The most promising or advanced approaches are summarized in Table 1 .
Concluding Remarks
Despite 
